BLOG

Sunday, October 6, 2019

Cipla's unbranded drug business may take a hit in FY20, say analysts

Analysts see full recovery by Q3 as company revamps distribution network

from Home Page https://ift.tt/31SzSvH
via IFTTT
at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO

However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...